Is the fervor over Ozempic just a passing fad? It doesn't appear to be the case after Novo Nordisk (NYSE: NVO) announced its results for the first nine months of 2023 on Thursday morning.

Ozempic sales soared in the third quarter. Unsurprisingly, investors reacted positively to Novo Nordisk's results, with the big drugmaker's shares jumping nearly 4% in early trading.

However, Eli Lilly (NYSE: LLY) reported its Q3 results on Thursday as well, and its share price jumped close to 7%. Is Lilly a better stock to buy than Novo Nordisk?

Continue reading

Source Fool.com